NASDAQ$TCRX
Tscan Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
TScan Therapeutics reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.
TScan Therapeutics reported second quarter 2024 financial results, including revenue of $0.5 million and a net loss of $31.7 million. The company received RMAT designation for TSC-100 and TSC-101 and engaged a CDMO for manufacturing. They expect to report initial data from the solid tumor program and one-year data from the ALLOHATM Phase 1 heme trial by the end of 2024 and cash is expected to fund operations into Q4 2026.
- FDA granted RMAT designation to TSC-100 and TSC-101 for AML, ALL, and MDS treatment.
- Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization.
- On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024.
- Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026.
Headline financials
Revenue & EPS history
Tscan Therapeutics · Revenue · Quarterly
$536K
Revenue by segment
Tscan Therapeutics · $3.89M total across 1 segment · Q3 2023
- Collaboration & License$3.89M—100.0%
Forward guidance
TScan anticipates several milestones in their Heme Malignancies and Solid Tumor programs.
Tailwinds
- Opening of expansion cohorts at the proposed recommended Phase 2 dose level to further characterize safety and evaluate translational and efficacy endpoints is planned for the third quarter of 2024.
- Reporting of one-year clinical and translational data on initial patients is anticipated by the end of 2024.
- Initiation of a registration trial, pending feedback from regulatory authorities, and reporting of two-year clinical and translational data are anticipated in 2025.
- Initial singleplex data expected by the end of 2024.
- Response data for multiplex therapy anticipated in 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
+1.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-5.7%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+32.4%
Q1 2023
Best reaction
-18.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | -3.3% | -18.9% | |
| Q4 2025 | +4.9% | +19.8% | -2.4% | |
| Q3 2025 | +0.8% | -20.5% | -17.2% | |
| Q2 2025 | +3.1% | +11.8% | +14.9% | |
| Q1 2025 | -4.6% | +0.8% | +18.3% | |
| Q4 2024 | +2.6% | +7.7% | -7.1% | |
| Q3 2024 | -7.9% | -22.6% | -47.0% | |
| Q2 2024 | -1.0% | -3.0% | -3.9% | |
| Q1 2024 | +16.3% | +16.2% | +14.9% | |
| Q4 2023 | +1.6% | -6.7% | +0.9% | |
| Q3 2023 | +3.0% | +14.9% | +50.8% | |
| Q2 2023 | -4.2% | -2.3% | +12.1% | |
| Q1 2023 | +32.4% | +18.5% | -14.4% | |
| Q4 2022 | -8.5% | -23.0% | -33.3% | |
| Q3 2022 | -0.4% | +3.9% | -20.6% | |
| Q2 2022 | -10.8% | -18.8% | -20.5% | |
| Q1 2022 | +10.6% | +38.3% | +80.0% | |
| Q4 2021 | +7.8% | -1.6% | -37.8% | |
| Q3 2021 | +2.2% | -4.4% | -28.0% | |
| Q2 2021 | -18.2% | -21.7% | -53.7% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro